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Abstract 
Background: Development of theranostic concepts that include inductively coupled plasma mass 
spectrometry (ICP-MS) and laser ablation ICP-MS (LA-ICP-MS) imaging can be hindered by the 
lack of a direct comparison to more standardly used methods for in vitro and in vivo evaluation; e.g. 
fluorescence or nuclear medicine. In this study a bimodal (or rather, hybrid) tracer that contains 
both a fluorescent dye and a chelate was used to evaluate the existence of a direct link between 
mass spectrometry (MS) and in vitro and in vivo molecular imaging findings using fluorescence and 
radioisotopes. At the same time, the hybrid label was used to determine whether the use of a 
single isotope label would allow for MS-based diagnostics. 
Methods: A hybrid label that contained both a DTPA chelate (that was coordinated with either 
165Ho or 111In) and a Cy5 fluorescent dye was coupled to the chemokine receptor 4 (CXCR4) 
targeting peptide Ac-TZ14011 (hybrid-Cy5-Ac-TZ4011). This receptor targeting tracer was used 
to 1) validate the efficacy of (165Ho-based) mass-cytometry in determining the receptor affinity via 
comparison with fluorescence-based flow cytometry (Cy5), 2) evaluate the microscopic binding 
pattern of the tracer in tumor cells using both fluorescence confocal imaging (Cy5) and 
LA-ICP-MS-imaging (165Ho), 3) compare in vivo biodistribution patterns obtained with ICP-MS 
(165Ho) and radiodetection (111In) after intravenous administration of hybrid-Cy5-Ac-TZ4011 in 
tumor-bearing mice. Finally, LA-ICP-MS-imaging (165Ho) was linked to fluorescence-based analysis 
of excised tissue samples (Cy5).  
Results: Analysis with both mass-cytometry and flow cytometry revealed a similar receptor affinity, 
respectively 352 ± 141 nM and 245 ± 65 nM (p = 0.08), but with a much lower detection sensitivity 
for the first modality. In vitro LA-ICP-MS imaging (165Ho) enabled clear discrimination between 
CXCR4 positive and negative cells, but fluorescence microscopy was required to determine the 
intracellular distribution. In vivo biodistribution patterns obtained with ICP-MS (165Ho) and 
radiodetection (111In) of the hybrid peptide were shown to be similar. Assessment of tracer 
distribution in excised tissues revealed the location of tracer uptake with both LA-ICP-MS-imaging 
and fluorescence imaging.  
 
Ivyspring  
International Publisher 
 Theranostics 2017, Vol. 7, Issue 3 
 
 
http://www.thno.org 
625 
Conclusion: Lanthanide-isotope chelation expands the scope of fluorescent/radioactive hybrid 
tracers to include MS-based analytical tools such as mass-cytometry, ICP-MS and LA-ICP-MS 
imaging in molecular pathology. In contradiction to common expectations, MS detection using a 
single chelate imaging agent was shown to be feasible, enabling a direct link between nuclear 
medicine-based imaging and theranostic methods. 
Key words: bimodal, fluorescence, molecular imaging, molecular pathology, mass spectrometry, mass 
cytometry, LA-ICP-MS imaging, radioisotopes, SPECT. 
Introduction 
The use of technologies based on inductively 
coupled plasma (ICP) mass-spectrometry (MS), in the 
form of MS-based cytometry and laser ablation 
ICP-MS (LA-ICP-MS) imaging for mass spectrometry 
immunohistochemistry (MSIHC), is gaining attention 
in molecular pathology. Along with the multiplexing 
potential (e.g. ability to detect multiple targets within 
one sample) of this technology, its wide dynamic 
range and the absence of background effects due to 
autofluorescence shows promise in the elucidation of 
molecular profiles. This does, however, require 
receptor-targeting vectors (e.g. antibodies) that are 
functionalized with non-ionizing lanthanide isotopes. 
[1,2,3] 
The use of MS-labels that contain a single 
lanthanide isotope theoretically allows for 
multiplexing of up to 100 targets. Such a level of 
multiplexing cannot be achieved using standard 
brightfield microscopy or fluorescence detection 
techniques, in spite of development of advanced 
sequential methods such as dye-cycling.[4] 
Isotopically enriched stable isotopes are expensive but 
mono-isotopic elements (e.g. 165Ho) can be accurately 
detected with a higher sensitivity. This means that in 
MS approaches mono-isotopic elements are preferred 
over isotopes that convey multiple masses (e.g. 
158Gd).[5] To generate MS-dedicated tracers, targeting 
vectors are generally functionalized with 
(commercially available) polymeric structures that 
contain 130-160 chelates and the corresponding 
number of non-ionizing metal (most often lanthanide) 
isotopes, e.g. 113In, 176Lu or 165Ho.[2] Unfortunately the 
molecular weight of these “large” polymeric MS-tags 
is close to that of an antibody or protein (100-150 kD) 
and can therefore influence the properties of the 
binding vector.[6] In nuclear medicine identical or 
similar targeting vectors labeled with only a “small” 
single chelate (Mw: 540 Da [7]) and a single 
radioisotope atom (e.g. 111In, 177Lu or 166Ho) are used 
for both imaging and therapy.[8] It is important to 
note that in nuclear medicine one aspect of tracer 
optimization has always been to minimize the impact 
of imaging labels on the receptor affinity and in vivo 
kinetics of targeting vectors. Hereby the size and 
chemical characteristics of the label influences the 
overall properties of the tracer. [9-11] 
Through theranostics, the fields of 
radio-immunotherapy and peptide-based systemic 
radionuclide therapy have started to gain ground.[12, 
13] Because of their economic and practical 
advantages over antibodies (e.g. lower production 
cost, easier GMP manufacturing protocols and 
improved pharmacokinetics), peptides are 
increasingly applied in the clinic.[14] Without 
changing the tracer, diagnostic and therapeutic 
applications of peptides can be linked through the use 
of two different (radio)isotopes, e.g. 111In or 68Ga for 
diagnostic applications and 177Lu, or 90Y for 
therapeutic applications. Some radioisotopes almost 
seem to be tailored towards such combined use. For 
example, 166Ho provides two different emission types; 
γ-rays for scintigraphy and β-particles for therapeutic 
applications.[15] 
A promising oncologic target that has been 
pursued successfully in a peptide-based theranostic 
set-up is the chemokine receptor 4 (CXCR4) [16, 17]; 
CXCR4 expression is directly related to the 
malignancy and metastatic nature of cancer.[18, 19] 
Depending on the type of label one wants to 
introduce, there are different targeting vectors 
available for CXCR4.[20] Here one should consider 
that, for now, fluorescent or bimodal (or rather 
hybrid) labels seem to require a (larger) targeting 
vector, e.g. Ac-TZ14011. 
While the effectiveness of theranostic concepts 
can be proven in vivo using tumor models, their early 
phase development can be hindered by the inability to 
microscopically analyze the tracer-uptake in cells (in 
vitro) and tissue (ex vivo). In a different setting, namely 
that of image-guided surgery, the use of hybrid 
imaging tracers allowed successful integration of 
non-invasive diagnostic imaging (based on the 
radioisotope) with detailed analysis of pathological 
tissue sections (based on fluorescence).[21-24] 
Theoretically, the fluorescent component in hybrid 
tracers could help to provide a direct link between MS 
and radioisotope-based findings. At the same time, 
the use of a hybrid label could also help in 
determining whether “large” multi-chelate labels are 
indeed absolutely required for MS-based diagnostics. 
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To study these concepts, the CXCR4 targeting peptide 
Ac-TZ14011 was functionalized with a hybrid label 
that contained a diethylenetriaminepentaacetic acid 
(DTPA) chelate and a Cy5 fluorescent dye (Scheme 
1A). Application of this hybrid tracer was used to: 1) 
validate the efficacy of (165Ho-based) mass-cytometry 
in determining the receptor affinity of targeting 
peptides (in this case the CXCR4 targeting peptide 
Ac-TZ14011) via comparison to fluorescence-based 
flow cytometry (Cy5; Scheme 1B), 2) evaluate the 
microscopic binding pattern of the tracer in tumor 
cells using both fluorescence confocal imaging (Cy5) 
and LA-ICP-MS-imaging (165Ho; Scheme 1B), 3) 
compare in vivo biodistribution patterns obtained 
with ICP-MS (165Ho) and radiodetection (111In) in 
tumor-bearing mice (Scheme 1C), and 4) link 
LA-ICP-MS-imaging (165Ho) to the molecular 
pathology of excised tissue samples (Cy5; Scheme 
1D).  
 
Materials and methods 
For synthesis and labeling of the 
Hybrid-Cy5-Ac-TZ14011 tracer, see the ‘Materials and 
methods’ section of the supporting information (SI). 
Flow cytometry 
MDAMB231 and MDAMB231 X4 human breast 
cancer cells [25] were trypsinized and aliquoted in 
portions of 300000 cells. For details on the culturing 
conditions, see the SI. For saturation binding 
experiments, different concentrations of 
hybrid-Cy5-Ac-TZ14011 ranging between 0 and 1000 
nM in 50 μL of 0.1% bovine serum albumin (BSA) in 
PBS were added. Cells were incubated for 1 hr at 4 °C. 
The cells were washed three times with 300 μL of 0.1% 
BSA in PBS and re-suspended in 300 μL of 0.1% BSA 
in PBS. Fluorescence was measured using a LSRII 
flow cytometer (BD Biosciences) at APC-A settings 
(635 nm laser and 750 nm long pass filter). Live cells 
were gated on Forward Scatter, Side Scatter and Pulse 
Width, and 20000 viable cells were analyzed. All 
experiments were performed in triplicate (total n=6). 
 
 
 
 
Scheme 1. Schematic 
overview of the use of 
hybrid tracers in 
theranostic applications. 
A) Components that make up 
the hybrid tracer used to 
target CXCR4: a 
Cy5-fluorescent dye, a 
DTPA-chelate and the 
CXCR4 targeting peptide 
Ac-TZ14011. After 
functionalization with either a 
radioisotope (radiolabel; 
yellow) or a non-ionizing 
lanthanide isotope (blue), this 
tracer also becomes of value 
for respectively nuclear 
medicine (NM) or mass 
spectrometry (MS) based 
applications. B) In vitro this 
tracer can be used in 
fluorescence (FL)- (red) and 
MS-based cytometry and 
imaging studies. C) In vivo 
NM-based imaging studies can 
be complemented with NM- 
or MS-based analysis of 
uptake levels in tissues and D) 
ex vivo FL- and MS-based 
imaging could be used to 
evaluate the degree and 
heterogeneity of tissue 
staining following in vivo tracer 
administration. 
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Mass cytometry 
0.5 x 106 MDAMB231 X4 and 0.5 x 106 
MDAMB231 cells were aliquoted per sample, to 
which 1 mL of 1:500 diluted 500 µM 103Rh DNA 
intercalator (Fluidigm) with Staining Buffer 
(Fluidigm) was added for 15 minutes at RT to stain 
dead cells as the dye only enters cells when cell 
membranes are compromised. Subsequently, cells 
were washed twice with Staining Buffer (Fluidigm). 
250nM (165Ho)hybrid-Cy5-Ac-TZ14011 was added to 
the cells, and incubated for 1 hour at 4ºC. Following 
incubation, cells were washed twice with Staining 
Buffer. Hereafter cells were incubated with 1 mL of 
1:1000 diluted 125 μM DNA intercalator-Ir 
(containing 191Ir and 193Ir in MaxPar Fix and Perm 
Buffer (Fluidigm)) overnight at 4ºC to stain all cells. 
Hereafter cells were centrifuged at 2500 rpm and the 
supernatant discarded. Cells were washed twice with 
Staining Buffer followed by two washing steps with 
MilliQ water (MQ). Prior to data acquisition, cell 
pellets were diluted in MQ water containing 1:10 
diluted EQ Four Element Calibration Beads 
(Fluidigm) to the concentration of 0.5 *106 cells/mL to 
achieve an acquisition rate of 500 events/s on the 
CyTOF 2TM mass cytometer (Fluidigm). Data was 
acquired and analyzed using dual-count mode and 
noise-reduction on. After data acquisition, the mass 
bead signal was used to normalize the short-term 
signal fluctuations with the reference EQ passport 
P13H2302 during the course of each experiment and 
the bead events were removed. Data analysis was 
performed with FlowJo v10.1 (Tree Star Inc.). 
Determination of the dissociation constants is 
described in the SI. 
Fluorescence imaging of cells 
For details on the sample preparation for 
imaging of cells, see the SI. Confocal imaging was 
performed on viable cells, using an SP8 WLL 
fluorescence confocal microscope (Leica). Cells were 
incubated with hybrid-Cy5-Ac-TZ14011 (1mg/ml, 
1:200) for 1 hr at 40C and washed three times with 
medium. Prior to imaging the nuclei of the cells were 
stained with Hoechst 33342 (ThermoFisher Scientific). 
Sequential scanning settings were used to visualize all 
fluorescent features; Cy5 (ex 633 nm, em 650-700 nm), 
GFP (ex 488 nm, em 525-575 nm) and Hoechst (ex 405 
nm, em 425-474 nm). A maximum intensity projection 
(MIP) of 25 separate images over approximately 10um 
(height of the cell) was used to obtain a 3D 
representation of the sample. For the evaluation of the 
variation in the staining over time images were 
obtained over 60 minutes, with a 2 minute time 
interval. Intensity profiles and pixel counts were 
obtained with ImageJ (ImageJ 1.45s). 
MS imaging of cells 
Slides with cells were washed twice with PBS, 
incubated with 250 nM (165Ho)hybrid-Cy5-Ac- 
TZ14011 for 1 hr at 40C and fixed in a 4% Formalin 
solution.  
For ICP-MS imaging a commercial LA system 
(New Wave 213, Portland, USA) carried out with a 
beam expander and laser spot sizes between 4 µm and 
250 µm, was attached to an ICP-SF-MS device 
(Element XR, Thermo Fisher Scientific). For imaging 
165Ho was selected and a 15 µm laser spot (213 nm, 5 
µm overlap, “real” spot size 10 µm), 15 µm/s scan rate 
and 20 Hz repetition rate were used. Samples were 
completely ablated line by line under optimized 
LA-ICP-MS conditions (ablation gas flow: 1 L min-1 
He, RF plasma source: 1350 W, plasma gas flow: 16 L 
min-1 Ar, auxillary gas flow: 1.1 L min-1 Ar). ImageJ 
was used to create intensity profiles or color-coded 
images by transforming the scan time into a 
micrometer scale.  
In vivo SPECT imaging 
Details on the generation of the in vivo tumor 
model can be found in the SI. Mice were injected 
intravenously with (111In)hybrid-Cy5-Ac-TZ14011 (50 μg, 
10 MBq) and imaged at 24 hrs post-injection (n=5). 
Animals were anesthetized with a mixture of 
Hypnorm, Dormicum and water suitable for injection; 
1:1:2; 5μL/gr intraperitoneal (i.p.), prior to placement 
onto a dedicated positioned bed of a three-headed 
U-SPECT (MILabs, Utrecht, The Netherlands). 
Radioactivity counts from total body scans were 
acquired over 45 minutes using a 0.6 mm mouse 
multi-pinhole collimator in list mode data. For 
reconstruction from list mode data, the photo-peak 
energy window was centered at 171 and at 245 keV 
with a window width of 20%. Side windows of 5% 
were applied to correct for scatter and down scatter 
corrections. The image was reconstructed using 6 
pixel based ordered subset expectation maximization 
iterations (POSEM) with 16 subsets, unfiltered 0.2 mm 
isotropic voxel size and with decay and triple energy 
scatter correction integrated into the 
reconstruction.[26] Volume-rendered images were 
generated from 4 mm slices and analyzed using 
Matlab R2014a software (v 8.3.0.532, MatWorks®). 
Images were generated using maximum intensity 
projections (MIP). A Gaussian filter of 1.65 mm full 
width at half maximum (FWHM) was applied to the 
3D data to suppress small scale non-uniformities and 
the color scale threshold was adjusted to achieve 
optimal lesion identification.[27] Images were 
reconstructed and evaluated by using identical 
settings and cut-off values. After imaging the mice 
were included in the biodistribution study. 
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Biodistribution Studies 
Mice were sacrificed at twenty-four hours after 
intravenous injection of 50 μg of 
(111In)hybrid-Cy5-Ac-TZ14011, (165Ho)hybrid-Cy5-Ac- 
TZ14011 or 111In(165Ho)hybrid-Cy5-Ac-TZ14011 (10 
MBq, n=3-5 for each group), and tissues were excised 
and weighed individually. Samples containing both 
labels were first divided in half before being weighed; 
One part was used to measure the content of 
radioactivity, the other part was used for lanthanide 
detection. The level of radioactivity present in the 
tissues containing the radiolabeled compound was 
counted using a gamma counter (2470 automatic 
gamma counter, Perkin–Elmer, 245 keV, 60 s). Counts 
per minute were converted into 1) the total amount of 
111In atom counts and 2) MBq, and corrected for decay 
and counting efficiency. The percentage of the 
injected dose per gram of tissue (% ID/g) was 
calculated as follows: [(MBq measured in 
tissue/injected dose) X 100%]/weight of tissue. The 
total amount of 111In atom counts per gram of tissue 
was calculated by dividing the total amount of 111In 
counts by the weight of the tissue. 
Lanthanide-containing tissue samples were freeze 
dried before the tissue was degraded in boiling 69% 
nitric acid (Traceselect) in 20 mL glass scintillation 
vials. Note: especially in high-content organs such as 
the liver and kidneys destruction of small parts of the 
tissues (>1.0 g) was required to realize accurate 
measurement outcomes. Samples were heated in a 
sand bath at 120 °C until nearly dry and after cooling 
were subsequently re-dissolved in 2 mL 1.5 % nitric 
acid.[28] 165Ho content was measured on a Thermo X 
series-2 ICP-MS system equipped with an 
auto-sampler and a conical glass concentric nebulizer 
and operated at an RF power of 1400 W. Data 
acquisition was performed in the selected ion 
monitoring mode at m/z ratio of 165 that is 
characteristic for 165Ho. Quantification was based on 
ionic 165Ho standard diluted in the same acidic matrix. 
The percentage of the injected dose per gram of tissue 
(% ID/g) was calculated as follows: [(amount of 165Ho 
isotopes measured in tissue/injected dose) x 
100%]/weight of tissue. The total amount of 165Ho 
atom counts per gram of tissue was calculated by 
dividing the total amount of 165Ho counts by the 
weight of the tissue. 
Imaging of tissue sections 
Frozen tissue sections (4 μm thickness) obtained 
from tissues that were excised during the distribution 
study were used for both fluorescence- and scanning 
mass-spectrometry imaging of tissues. 
Fluorescence imaging of tissues 
Tissue sections nuclei were stained using 25 μl of 
Prolong Gold DAPI (4’,6-diaminidino-2- 
phenylindole) mounting medium (Thermofisher 
Scientific). The hybrid-Cy5-Ac-TZ14011 content of the 
sections was visualized at a 10x magnification using a 
DM5500 fluorescence microscope (Leica) using Cy5 
and DAPI settings and Colorpic software. Intensity 
profiles and pixel counts were obtained with ImageJ.  
MS-imaging of tissues 
LA-ICP-MS imaging was performed using a 193 
nm ArF*excimer-based Analyte G2 LA-unit (Teledyne 
CETAC Technologies) hyphenated to complement a 
quadrupole-based ICP-MS device. For imaging, a 
laser spot size of 15 µm diameter (5 µm overlap and a 
actual spatial resolution of 10µm), 15 µm s-1 
translation speed and 20 Hz repetition rate were 
selected. 
Statistics 
Statistics were performed using a standard 
unpaired t-test. 
Results 
Receptor affinity (Mass-cytometry vs. flow 
cytometry) 
Direct comparison between fluorescence- 
cytometry and mass-cytometry for assessment of the 
tracer affinity was achieved via the evaluation of 
identically prepared cell samples using different 
methods. For fluorescence-based flow-cytometry the 
Cy5 signal was used as readout. This resulted in an 
affinity of 245 ± 65 nM using non-functionalized 
hybrid-Cy5-Ac-TZ14011 or hybrid-Cy5-Ac-TZ14011 
functionalized with 165Ho. These values are in 
agreement with previous reports using different 
conjugates from the same peptide (functionalized 
with slightly different imaging labels; e.g. DTPA, a 
fluorescent dye alone and a different hybrid label).[20] 
Mass-cytometry measurements using 165Ho-hybrid- 
Cy5-Ac-TZ14011 provided a KD value that was not 
significantly different (p = 0.08) from the values found 
using fluorescence, namely 352 ± 141 nM (Figure 1A). 
However, the relatively low maximum signal 
intensity obtained with mass-cytometry (being 65 
atom counts vs. 1100 fluorescence counts) could be 
seen as a weakness of this detection method. 
Fluorescence microscopy vs. 
LA-ICP-MS-imaging of cells 
The uptake specificity and cellular localization of 
binding of (165Ho-)hybrid-Cy5-Ac-TZ14011 was 
evaluated using both fluorescence confocal 
microscopy and LA-ICP-MS imaging. This was 
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performed using basal CXCR4 expressing 
MDAMB231 cells and CXCR4 overexpressing 
MDAMB231 X4 cells. Cy5-based fluorescence imaging 
(Figure 1Bii) revealed clear localization at the 
membrane of the MDAMB231 X4 cells (10-20 μm in 
diameter; maximum signal intensity: 2*104 pixel 
counts), which corresponds to the GFP signal of the 
CXCR4 receptor; in this cell-line, GFP was fused to the 
CXCR4 receptor (See SI, Figure SI1).[25] A 3D image 
of these samples (maximum intensity projection (MIP) 
of 25 separate images over approximately 10 μm 
(height of the cell)) revealed the complete staining 
pattern of the cells (Figure 1Biii). No clear signal could 
be detected in the MDAMB231 cells.  
Using LA-ICP-MS imaging, uptake of 
165Ho-hybrid-Cy5-Ac-TZ14011 was clearly seen in the 
MDAMB231 X4 cells (maximum signal: 1*104 165Ho 
atom counts), while the signal measured in the 
MDAMB231 cells did not significantly exceed the 
background signal (1*102 165Ho atom counts; Figure 
1C). Unfortunately, the resolution of MS-imaging 
(lateral resolution: 10 μm) did not allow for in-plain 
imaging, and thus only provided a more global 
distribution pattern of (Figure 1Cii). 
 
 
Figure 1. Determination of the receptor affinity via fluorescence-cytometry and mass-cytometry. A) Concentration-dependent saturation curves 
generated upon measurement of the mean amount of fluorescent counts (FC: fluorescence-cytometry; blue), or the average amount of 165Ho-isotopes (MC: 
mass-cytometry; green) in each cell sample (n=6 for both methods). B) Fluorescence microscopy of viable CXC4 overexpressing MDAMB231 X4 (top images) and 
basal CXCR4 expressing MDAMB231 cells (bottom images) after incubation with 165Ho-hybrid-Cy5-Ac-TZ14011; i = brightfield image, ii = single plane confocal 
image, iii = 3D confocal image (MIP). C) LA-ICP-MS imaging image of similar cell samples that were formalin fixed after incubation for 1hr with 
165Ho-hybrid-Cy5-Ac-TZ14011. 
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In vivo biodistribution patterns  
In vivo radioactivity-based imaging was 
performed in mice using SPECT after intravenous 
injection of 111In-hybrid-Cy5-Ac-TZ14011 
(tracer-labeling: 10 MBq/mouse, 3.5*1011 111In atoms; 
Figure 2A). These images revealed a high uptake in 
the liver and kidneys as well as in the tumor (T). Ex 
vivo analysis (Figure 2B, blue bars and Figure 2C) 
revealed that uptake in the tumor exceeded the 
uptake in muscle by a factor 6 (respectively 9.2*108 ± 
2.6*108 and 1.5*108 ± 3.1*106 111In atom counts, tumor 
to muscle ratio (T/M): 5.95 ± 0.39).  
Radioisotope-based assessment of samples that 
contained 111In(165Ho)-hybrid-Cy5-Ac-TZ14011 (tracer 
labeling with 111In, followed by saturation with 
7.5*1015 165Ho atoms) gave highly similar results 
(Figure 2B, red bars). The highest level of uptake was 
also found in the liver and kidneys (respectively 
1.4*1011 ± 1.9*1010 and 9.6*1010 ± 9.69*1010 111In atom 
counts/gram tissue), with lower, but significant, uptake 
levels in the tumor (Figure 2B; 9.2*108 ± 2.2*108 111In 
atom counts/gram tissue) and a T/M ratio of 4.38 ± 1.51. 
 When evaluating the 165Ho isotope content in 
the tissue samples (165Ho-hybrid-Cy5-Ac-TZ14011 
saturated with 7.5*1015 165Ho atoms; Figure 2B, blue 
bars), a similar trend in the distribution was seen with 
a comparable T/M ratio (5.85 ± 1,40). Overall the 
differences between the T/M ratio’s were not 
statistically significant and a strong correlation was 
observed between 111In-hybrid-Cy5-Ac-TZ14011 and 
111In(165Ho-)hybrid-Cy5-Ac-TZ14011 (R2= 0.99627) as 
well as between 111In(165Ho-)hybrid-Cy5-Ac-TZ14011 
and 165Ho-hybrid-Cy5-Ac-TZ14011 (R2 = 0.99955). The 
higher count rates could be distributed to the 
saturated conditions in which 165Ho was applied. 
Hereby, the 104 fold difference in intensity between 
the tracer labeling (111In) and the 165Ho saturated 
condition was in agreement with the labeling-ratio, 
which was also 1:104 (111In:165Ho).  
165Ho-based LA-ICP-MS imaging vs. 
fluorescence imaging in excised tissue samples.  
Next to the %ID/g evaluation, the distribution of 
165Ho-hybrid-Cy5-Ac-TZ14011 was visualized in 5μm 
thick fresh frozen tissue sections, via both LA-ICP-MS 
imaging (Figure 3A and B) and fluorescence 
microscopy (Figure 3C). A homogeneous distribution 
was observed in liver tissue, while for tumor tissue a 
heterogeneous distribution was observed with both 
imaging techniques (max intensity 2*104 for 
LA-ICP-MS and 6*104 for fluorescence imaging).  
 
 
Figure 2. In vivo biodistribution of hybrid-Cy5-Ac-TZ14011. The biodistribution was evaluated via A) in vivo SPECT imaging (L= liver, K= kidney, M= muscle 
and T = tumor (encircled in red)) and B) by assessment of the atom counts per gram of tissue using gamma counting (radiodetection after injection of 
111In-hybrid-Cy5-Ac-TZ14011 (red bars) or 111In(165Ho)-hybrid-Cy5-Ac-TZ14011 (purple bars)) or ICP-MS after injection of 165Ho-hybrid-Cy5-Ac-TZ14011 (blue 
bars). C) Overview of the percentage of the injected dose per gram of tissue (%ID/g) of 111In-hybrid-Cy5-Ac-TZ14011 (111In-hybrid), 
111In(165Ho)-hybrid-Cy5-Ac-TZ14011 (111In(165Ho)-hybrid) and 165Ho-hybrid-Cy5-Ac-TZ14011 (165Ho-hybrid). 
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Figure 3. Ex vivo analysis of the distribution of hybrid-Cy5-Ac-TZ14011 in tissue sections. A) Color overlay of the 165Ho-signal intensity map as obtained 
using LA-ICP-MS on standard photographic images of the whole tissue section (max intensity: 2*104 165Ho atoms). Individual images were obtained using a 2.5x 
magnification, the complete overview was obtained after stitching of these images. B) More detailed 165Ho signal intensity map of the area within the red rectangle. The 
linearly scaled color bar on the right presents the 165Ho signal intensity. C) Fluorescence images of consecutive tissue sections at 5x magnification showing a more 
detailed staining pattern (max pixel intensity: 6*104). Cell nuclei were stained blue using DAPI containing Proline Gold mounting medium. 
 
Discussion 
The hybrid LA-ICP-MS-fluorescence- 
radioactivity approach enabled a critical 
intra-methodological evaluation of ICP-MS-based 
diagnostics in relation to fluorescence- and 
radioisotope-based methods. The use of a single 
isotope containing imaging label preserved the 
receptor affinity and allowed for detailed in vitro, in 
vivo and ex vivo analysis using the different 
modalities. This direct comparison revealed not only 
the strengths but also the weaknesses of 
ICP-MS-based diagnostics, thereby providing insight 
into how ICP-MS-based analysis may best fit within 
the realm of theranostics.  
In the current theranostic setting interchanging 
of isotopes empowers both diagnostic and therapeutic 
applications, while using the same tracer. Ho-based 
theranostic approaches are increasing and insight in 
to their function could possibly be enhanced further 
through the use of MS-compatible 
165Ho-isotopes.[8,12] Uniquely, Ho-isotopes are also 
MRI compatible, allowing their use in a combined 
SPECT and MRI approach.[29] This feature could be 
explored in a future extension of the described 
approach. 
 When using CXCR4-overexpressing cells, a 
single isotope was shown to be sufficient for 
determination of the KD using MS-cytometry. 
However, the count rates obtained with 
mass-cytometry were a 17-fold lower than the count 
rates obtained with fluorescence-based flow 
cytometry (Figure 1A). Although the 165Ho-related 
background signal was almost nonexistent, these low 
count rates induced a higher variance. At first glance, 
signal amplification via functionalization with a 
multiple-chelate-containing imaging label would 
provide the necessary increase in mass-cytometry 
signal. However, the other studies presented using 
LA-ICP-MS or ICP-MS analysis of tissue (extracts) do 
not indicate that there is a requirement to enhance the 
MS-signal intensity. This suggests that improvements 
in the ion transmission and detector sensitivity of 
MS-cytometry provide the most straightforward 
approaches to improve sensitivity. Such 
improvements would overcome the need to introduce 
“large“ labels that would certainly disrupt the delicate 
balance between the affinity of the Ac-TZ14011 
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targeting moiety and the size of the label.[20] This is 
highly relevant as even antibodies with and without a 
polymeric MS-label revealed that, a 2-27% reduction 
in signal intensity for the antibody that was 
functionalized with the polymeric label, even while 
the target specificity of the antibodies was retained.[1]  
 The results from the direct comparison between 
the T/M ratio obtained with the radioisotope-based 
approach and ICP-MS analysis showed the possible 
utility of ICP-MS in this application (Figure 2). 
However, the methodology used for tissue 
destruction was of great importance for the 
effectiveness of the ICP-MS analysis of liver and 
kidney specimens.[28,29] Possibly isotope recovery 
using small tissue fragments can be further improved 
by implementing microwave-based digestion instead 
of hot plate-based chemical extraction.  
In cells, both fluorescence- and LA-ICP-MS 
imaging enabled discrimination between 
CXCR4-overexpressing and non-overexpressing cells. 
Where fluorescence imaging can be hindered by e.g. 
autofluorescence and signal scattering [14, 24, 30], 
LA-ICP-MS imaging is not. In tissue 165Ho-based 
MS-imaging showed intensity differences between 
tissue types but also heterogeneous distribution 
within the tissue sections itself (Figure 3). The 20 μm 
beam-size used in LA-ICP-MS imaging only enabled 
visualization of the entire cell. With fluorescence 
(confocal) microscopy a resolution of approximately 
200 nm can be obtained, which enabled visualization 
of organelles such as lysosomes within a cell (Figure 1 
and Figure SI1). Ongoing efforts on improving the 
(spatial) resolution and detection sensitivity of 
MS-imaging might help bring these resolutions closer 
together.[31] Using this hybrid approach, the 
radioactive signature could also be exploited for 
autoradiography purposes, providing yet another link 
between the different methods. 
The combined use of a lanthanide isotope, a 
radioisotope and a fluorescent dye has allowed us to 
cross-validate mass-cytometry, solution based 
LA-ICP-MS and LA-ICP-MS imaging findings. The 
increasing availability of the chelate (or hybrid) 
labeled targeting vectors provides ground for future 
expansion of this approach. The evaluation of 
multiple receptors in one sample (multiplexing), via 
the use of multiple MS-isotopes, would even enable 
assessment (and validation) of multiple targets in one 
sample. Selection of the receptor with the highest 
expression level could then even be used to tailor 
imaging and/or therapeutic approaches, to the 
expression profile of a lesion in one specific 
patient.[22]  
Conclusions 
Lanthanide-isotope chelation expands the scope 
of hybrid tracers to include MS-based analytical tools 
such as mass-cytometry, ICP-MS and LA-ICP-MS 
imaging. In contradiction to common expectations, 
MS detection using a single chelate imaging agent was 
shown to be feasible, enabling direct link with nuclear 
medicine based theranostic approaches.  
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Supplementary methods and figure.  
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